14 Feb Cannabics Pharmaceuticals Building a Diversified Portfolio of CDB-Based Products
Cannabics Pharmaceuticals (OTCQB: CNBX), an early-stage Biotechnology Company focussed on creating cannabinoid-based therapeutics and therapies for treatment of cancer, announced the signing of a Memorandum of Understanding (MoU) with RCK Medical Cannabis, an Israeli cannabis company that creates tailor-made medical cannabis strains and hybrid seeds to develop cannabis chemovars aimed at treating gastro intestinal cancers. The collaboration will see the Companies develop cannabis chemovars with cannabinoid profiles that possess antitumor properties and will act as the source strains for the creation of botanically derived active pharmaceutical ingredients (API’s), as per a Company statement.
Dr. Eyal Ballan, CTO and Co-Founder of Cannabics Pharmaceuticals commented,
“RCKMC is a pioneer in the field of plant genetics and breeding. Its expertise will synergize with Cannabics’ clinical capabilities to create the bases for proprietary drug development from seed to formulation.”
In January 2020, the Company had announced the results from a series of tests, performed through its High Through-put Screening (HTS) facility in Israel, which demonstrated the anti-tumor properties of cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol), on human gastrointestinal cancer cells. The tests were undertaken to study the necrosis effect of cannabinoids on gastrointestinal cancer cells, as well as other cancer cells and showed significantly higher rates of necrosis, when compared with other cannabinoids.
Dr. Yaakov Waksman, the company’s head of cannabidiol research, stated,
“My working assumption is that these results show that a correlation may exist between a cannabinoid’s Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumor activity, diminishing cancer cell’s viability rates. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell’s membrane, whereas their acidic form (CBCA and CBGA) – do not. This could explain the difference in anti-tumor activity rates demonstrated”.
Cannabics Pharmaceuticals (OTCQB: CNBX)
Market Cap: $54.33M; Current Share Price: 0.3894 USD
Data by YCharts
The Cannabis plant has an estimated 113 different compounds, out of which THC and CBD are the two main constituents. These affect the receptors in the brain to alter an individual’s physical and mental state. THC is mainly responsible for the psychoactive effects or the feeling of “high” caused by the use of cannabis. CBD on the other hand, has several powerful anti-inflammatory, analgesic, neuroprotective and anti-anxiety properties, which explains its growing popularity to treat a plethora of medical conditions. Unlike THC, CBD does not have any psychotropic effects and hence is widely preferred.
CBD is now being used to treat a wide array of medical conditions such as cancer, cardiovascular anomalies, arthritis, anxiety, depression and Insomnia. In addition, it has also been proven to possess neuroprotective benefits that can treat diseases such as seizures, Multiple Sclerosis (MS), Alzheimer’s, Parkinson’s and Schizophrenia to name a few. There is a growing preference for CBD over traditional pharmaceutical options as these have minimal side effects and are non-addictive.
In 2017, The WHO expert committee on Drug Dependence (ECDD) concluded that in its unadulterated form, CBD does not cause harm or have abuse potential. While further research is underway on the subject it has been proved that CBD is well tolerated in humans and is safe.
According to a report by Fortune Business Insights , the Global Gastric cancer treatment market is expected to be worth over USD 8.20 billion by 2026, growing at a CAGR of 15.3 percent. The American Cancer Institute estimates that 27,600 cases of stomach cancer will be diagnosed in 2020, and nearly 11,010 people will eventually succumb to it.
A survey conducted by Brightfield group shows that 42% of CBD users ditched traditional medicine and a significant 80% of the CBD users rated these alternate medicine as extremely effective treatment. The same survey reveals that 90% of CBD users were likely to buy these products again.
The Global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025, as per a report by Grand View Research, Inc, growing at a CAGR of 23.9%. There is a growing acceptance of the curative effects of cannabis, with some countries such as Canada and certain states of U.S legalizing the use of Marijuana for medical and recreational use. Research has time and again shown that cannabinoids (CBD), extracted from the cannabis plant, have varied medical uses with minimal side effects, making it a sought after alternative to traditional pharmaceutical options.
According to statistics published in the Hemp Business Journal, the industry registered sales of $820 million in 2017. In spite of facing regulatory hurdles and legal challenges, the industry grew by 16%.The industry is poised to grow to $2.1 billion by 2020, a whopping 700% increase from 2016. Those numbers are not only appealing to the players in the CBD market but also serve as an incredible opportunity the pharmaceutical companies to create novel solutions for disease with large unmet medical needs.
Cannabics Pharmaceuticals uses a proprietary High Content Screening (HCS) platform, which offers a combination of innovative screening tools and artificial intelligence, to develop personalized precision cancer medicine. The technology harnesses the power of naturally occurring cannabinoids to treat cancer. Cannabics HCS platform allows for the screening of numerous compounds derived from cannabis extracts and natural and synthetic cannabinoids, all stored in an extensive library, which also includes a cannabinoid matrix that can assess the effect of combining various compounds.
The Company’s proprietary High Content Screening (HCS) Platform, an automated cellular imaging and analysis platform helps automate various biological assays, besides enabling automated cellular imaging as well. In addition the Company utilizes state-of-the-art instruments such as Flow Cytometry, Automated Workstations and Multimode Microplate to gain valuable insights on the effects of cannabinoids on proliferation inhibition, apoptosis induction, angiogenesis and toxicity on cancerous cells as per a Company statement.
Cannabics is collaborating with SIMFO, a Germany based CTC lab, for carrying out in-vitro drug sensitivity tests on liquid biopsies using a cannabinoid sensitivity tests. CTC or circulating tumor cells act as valuable sources of tumor information as each cell contains a full cancer genome and transcriptome. They are very useful tools that can be used as predictive markers and used to analyze treatment outcomes.
The Company also undertakes the genetic profiling of individual patients in order to optimize the treatment plan and outcomes. The use of machine learning algorithms and deep learning models helps take into consideration an individual’s unique environmental and lifestyle data, which will help create customized and effective treatment plans.
In addition, the Company has also developed a proprietary capsule, which eliminates the need for vaping or smoking cannabis to derive benefit from the cannabis plant. The capsule has demonstrated long-lasting effects of near 10-12 hours and offers an oral, standardized, reliable and clinically tested route of administration.
The Company has successfully completed two clinical trials for Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS) and for the Screening of Potential Anticancer Cannabinoid Compounds. Cannabics research and development is based in Israel and has the patronage of the Ministry of Health to conduct scientific and clinical research on the efficacy of cannabinoid formulations in the treatment of cancer.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Click here to please visit our detailed disclosure